Severe Acute Respiratory-Syndrome Treatment Market Report 2026

The severe acute respiratory-syndrome treatment market size has grown rapidly in recent years. It will grow from $3.94 billion in 2025 to $4.53 billion in 2026 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to outbreaks of SARS-CoV and MERS-CoV, hospital-based treatment expansion, regulatory approval for antiviral drugs, growth in ICU capacity, awareness campaigns.

The severe acute respiratory-syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $8.33 billion in 2030 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to AI-assisted treatment protocols, development of novel antivirals, telemedicine-enabled critical care, global pandemic preparedness programs, investment in rapid diagnostics and treatment monitoring. Major trends in the forecast period include antiviral drug therapies, monoclonal antibodies, convalescent plasma therapy, tele-ICU integration, AI-based treatment monitoring.

The rising incidence of respiratory diseases is expected to drive the growth of the severe acute respiratory syndrome treatment market in the coming years. Respiratory diseases comprise a range of medical conditions that affect the respiratory system, which is responsible for breathing and gas exchange between the body and the external environment. Treatments for severe acute respiratory syndrome are used to alleviate symptoms, prevent respiratory failure, reduce inflammation, and maintain oxygen levels in patients with respiratory conditions. For example, in December 2023, the National Library of Medicine, a US-based medical library, reported that the global number of chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and older is projected to increase by 23% by 2050, reaching nearly 600 million. Therefore, the growing prevalence of respiratory diseases is fueling the growth of the severe acute respiratory syndrome treatment market.

Key companies in the severe acute respiratory syndrome treatment market are focusing on technological advancements, such as oral antiviral therapies that inhibit viral replication and reduce disease severity, to address rising demand from recurrent coronavirus outbreaks and the urgent need for effective outpatient treatments. For instance, in September 2025, Shionogi & Co., Ltd., a Japan-based pharmaceutical company, launched Ensitrelvir, the first oral antiviral therapy approved for the prevention and treatment of SARS-CoV infections. Ensitrelvir selectively inhibits the 3C-like protease, an enzyme essential for viral replication, providing a targeted mechanism that lowers viral load and alleviates symptoms more effectively than traditional supportive care. Its oral formulation allows for broader community access and early intervention, helping prevent severe disease progression. This innovation represents a significant advancement in managing SARS amid evolving viral strains and healthcare demands.

In February 2023, Vir Biotechnology, a US-based immunology company developing therapies for serious infectious diseases, partnered with GSK plc to advance next-generation COVID-19 and coronavirus solutions, either independently or with new partners, while continuing joint collaboration with GSK on sotrovimab and other respiratory-disease programs. GSK plc, based in the UK, develops vaccines, antibody platforms, and respiratory-virus research and development.

Major companies operating in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, AstraZeneca plc, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero Labs Ltd., Alexion Pharmaceuticals Inc., Cadila Healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, Panacea Biotec Limited, CureVac N.V., Inovio Pharmaceuticals Inc., Chimerix Inc.

North America was the largest region in the severe acute respiratory syndrome treatment market in 2025. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the severe acute respiratory-syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the severe acute respiratory-syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the severe acute respiratory syndrome treatment market by increasing the cost of imported antivirals, monoclonal antibodies, active pharmaceutical ingredients, and hospital-grade respiratory support products. Healthcare providers in Asia-Pacific and developing regions that rely on international pharmaceutical supply chains are facing higher treatment and inventory costs. These impacts are especially felt across intravenous and hospital pharmacy distribution channels. On the positive side, tariffs are stimulating local drug manufacturing and formulation capacity, strengthening national preparedness in the severe acute respiratory syndrome treatment market.

The severe acute respiratory-syndrome treatment market research report is one of a series of new reports that provides severe acute respiratory-syndrome treatment market statistics, including severe acute respiratory-syndrome treatment industry global market size, regional shares, competitors with a severe acute respiratory-syndrome treatment market share, detailed severe acute respiratory-syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the severe acute respiratory-syndrome treatment industry. This severe acute respiratory-syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Severe acute respiratory syndrome (SARS) is a serious form of pneumonia caused by an airborne virus that spreads through tiny droplets of saliva. It is a previously unrecognized virus from the Coronaviridae family, known as SARS-associated COVID-19 (SARS-CoV). Treatment for severe acute respiratory syndrome (SARS) involves medical interventions and supportive measures aimed at managing the symptoms and complications of this viral respiratory illness.

The main drug classes used in the treatment of severe acute respiratory syndrome include antibiotics, antivirals, corticosteroids, monoclonal antibodies, and others. Antibiotics are medications used to treat bacterial infections, working either by killing bacteria or inhibiting their growth, depending on the type. They are administered orally or intravenously for treating severe acute respiratory syndrome COVID-19 (SARS-CoV) and SARS-CoV-2. These medications are distributed through hospital pharmacies, retail pharmacies, and other channels.

The severe acute respiratory syndrome treatment market consists of revenues earned by entities by providing services such as respiratory therapy, oxygen therapy, ventilation, intensive care, isolation and infection control, fluid and electrolyte management and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The severe acute respiratory syndrome treatment market also includes sales of azithromycin, immunomodulators, vaccines, ribavirin, ritonavir, remdesivir, methylprednisolone, prednisolone, dexamethasone and interferon. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.